| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1001305932 |
| P356 | DOI | 10.2165/00003495-200060001-00003 |
| P698 | PubMed publication ID | 11129169 |
| P2093 | author name string | F Ciardiello | |
| P2860 | cites work | Epidermal growth factor-related peptides and their receptors in human malignancies | Q28293442 |
| Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor | Q28368986 | ||
| Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. | Q33539243 | ||
| Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors | Q33716113 | ||
| Protein tyrosine kinase inhibitors as novel therapeutic agents | Q33716122 | ||
| The epidermal growth factor receptor and its inhibition in cancer therapy | Q33716127 | ||
| Anticancer drug targets: growth factors and growth factor signaling | Q33808352 | ||
| Tyrosine kinase inhibitors in preclinical development | Q33832624 | ||
| Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents | Q33914337 | ||
| ZD1839 ('Iressa') as an anticancer agent | Q34112985 | ||
| Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice | Q34169387 | ||
| Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. | Q34507119 | ||
| Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy | Q34743875 | ||
| Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction | Q35975727 | ||
| Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines | Q36821859 | ||
| Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha | Q39999288 | ||
| Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. | Q40959114 | ||
| Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice | Q40971116 | ||
| Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity | Q41056981 | ||
| 4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity. | Q41313922 | ||
| Inhibitors of tyrosine kinase | Q41643303 | ||
| Therapeutic application of anti-growth factor receptor antibodies | Q41702457 | ||
| A specific inhibitor of the epidermal growth factor receptor tyrosine kinase | Q42834515 | ||
| In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor. | Q48025147 | ||
| Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor | Q57424632 | ||
| Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A | Q57424743 | ||
| Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain | Q69739616 | ||
| Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts | Q70487549 | ||
| Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor | Q71072552 | ||
| Tyrphostins. 6. Dimeric benzylidenemalononitrile tyrophostins: potent inhibitors of EGF receptor tyrosine kinase in vitro | Q71875718 | ||
| Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein | Q72132785 | ||
| Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies | Q72856071 | ||
| Epidermal growth factor receptor family and chemosensitization | Q73133036 | ||
| Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms | Q73803447 | ||
| Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase | Q73838278 | ||
| Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma | Q73886918 | ||
| Genistein exerts multiple suppressive effects on human breast carcinoma cells | Q77536071 | ||
| PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner | Q77553678 | ||
| Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model | Q77555291 | ||
| Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition | Q77556839 | ||
| P304 | page(s) | 25-32; discussion 41-2 | |
| P577 | publication date | 2000-01-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents | |
| P478 | volume | 60 Suppl 1 |
| Q44224981 | 25th European Society for Medical Oncology Congress. Hamburg, Germany. October 13-17, 2000. |
| Q34492884 | A multiscale computational approach to dissect early events in the Erb family receptor mediated activation, differential signaling, and relevance to oncogenic transformations |
| Q28486089 | A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer |
| Q37423291 | A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer |
| Q40732059 | Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor |
| Q35113656 | Advances in Molecular Therapies in Patients with Brain Tumors |
| Q36235557 | Antiangiogenic strategies in hepatocellular carcinoma: current status |
| Q47307070 | Arsenic attenuates Heparin-binding EGF-like growth factor/EGFR signalling that promotes matrix-metalloprotease-9-dependent astrocyte damage in the developing rat brain |
| Q44435268 | Bcl-xL Mediates a Survival Mechanism Independent of the Phosphoinositide 3-Kinase/Akt Pathway in Prostate Cancer Cells |
| Q92084099 | Bioassay Directed Isolation, Biological Evaluation and in Silico Studies of New Isolates from Pteris cretica L |
| Q35629076 | Cetuximab: in the treatment of metastatic colorectal cancer |
| Q28214310 | Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin |
| Q81232106 | Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1 |
| Q40677595 | Differential requirement of EGF receptor and its tyrosine kinase for AP-1 transactivation induced by EGF and TPA. |
| Q39841334 | Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation |
| Q59127611 | EpCAM ectodomain EpEX is a ligand of EGFR that counteracts EGF-mediated epithelial-mesenchymal transition through modulation of phospho-ERK1/2 in head and neck cancers |
| Q35162373 | Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. |
| Q35038746 | Epithelial growth factor receptor interacting agents |
| Q40582980 | Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors |
| Q37666880 | Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance |
| Q40354615 | Flow cytometry: a new approach for the molecular profiling of breast cancer |
| Q44634369 | Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer: Experience from a Single Institution |
| Q28740473 | Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF |
| Q34335662 | Growth factors and their receptors: new targets for prostate cancer therapy |
| Q36249234 | Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer |
| Q37320501 | Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. |
| Q74449248 | Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin |
| Q36681532 | Impact of molecular profiling on clinical trial design for glioblastoma. |
| Q37118974 | Implications of EGFR PharmDx kit for cetuximab eligibility |
| Q41826289 | Influence of macrocyclization on allosteric, juxtamembrane-derived, stapled peptide inhibitors of the epidermal growth factor receptor (EGFR). |
| Q38970301 | Inhibiting epidermal growth factor receptor at a distance |
| Q57003964 | Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours |
| Q37537093 | Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer? |
| Q35218002 | Mode of action of docetaxel - a basis for combination with novel anticancer agents |
| Q35790781 | Molecular biological design of novel antineoplastic therapies |
| Q47130146 | Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. |
| Q36936796 | Multimodality imaging of the HER-kinase axis in cancer |
| Q35149046 | New advances on prostate carcinogenesis and therapies: involvement of EGF-EGFR transduction system |
| Q44117392 | New therapeutic targets and strategies in lung cancer |
| Q34322733 | Pharmacogenetic determinants of anti-cancer drug activity and toxicity. |
| Q38968743 | Positional isomerization of a non-cleavable combi-molecule dramatically altered tumor cell response profile |
| Q28473949 | Potent cardioprotective effect of the 4-anilinoquinazoline derivative PD153035: involvement of mitochondrial K(ATP) channel activation |
| Q37073444 | Predictive and prognostic markers in colorectal cancer. |
| Q36813117 | Quantification of epidermal growth factor receptor expression level and binding kinetics on cell surfaces by surface plasmon resonance imaging |
| Q38292832 | Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach |
| Q93172097 | Role of cytokines in combinatorial immunotherapeutics of non-small cell lung cancer through systems perspective |
| Q44470573 | Synergistic antiproliferative and apoptotic effects induced by epidermal growth factor receptor and protein kinase a inhibitors in human prostatic cancer cell lines |
| Q35174501 | Targeting epidermal growth factor receptor--are we missing the mark? |
| Q34246558 | Targeting the EGFR signaling pathway in cancer therapy |
| Q38550459 | The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives. |
| Q28184932 | The direct interaction of phospholipase C-gamma 1 with phospholipase D2 is important for epidermal growth factor signaling |
| Q31073740 | The recent impact of solid-phase synthesis on medicinally relevant benzoannelated nitrogen heterocycles. |
| Q35094666 | The role of receptor tyrosine kinase inhibition in treating gastrointestinal malignancy |
| Q36273008 | The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical - and futuristic - perspective |
| Q35589206 | Tyrosine kinase inhibitors as cancer therapy |
| Q36623819 | ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. |
Search more.